Logo 1 Logo 2

Clinical Trial Details

Trial ID: L3603
Source ID: NCT02182895
Associated Drug: Saxagliptin
Title: Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient
Acronym:
Status: COMPLETED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT02182895/results
Conditions: Diabetes Mellitus
Interventions: DRUG: Saxagliptin
Outcome Measures: Primary: Mean Daily Blood Glucose Levels During Hospital, mean of average daily blood blood glucose for each patient day, Hospital days 2-5 | Secondary: Percentage of Blood Glucose Readings in 70-140 mg/dL Range, Percentage of BG readings in the desired range of 70-140 mg/dl out of all avaialble BG readings., Days 2 to 5|Dose of Insulin, Average daily amount of insulin used, Days 2 to 5|Incidence of Hypoglycemia (BG <70 mg/dL), Number of BG readings \<70 mg/dL in each group, Days 2 to 5|Incidence of Hyperglycemia (Blood Glucose >200 mg/dL), Proportion of BG readings in the severe hyperglycemic range., Days 2 to 5|Variability in Glucose Levels, Mean amplitude of glycemic excursions, Days 2 to 5|Length of Hospital Stay, Number of days in hospital, Admission to discharge, an expected average of 5 days|Patient Satisfaction, Diabetes Treatment Satisfaction Questionnaire - InPatient (DTSQ-IP). This questionnaire had 14 items that were scored on a scale of 0 to 6. Total score for each subjects could range from 0-84. Higher score means better satisfaction., At the time of discharge or Day 5
Sponsor/Collaborators: Sponsor: Brigham and Women's Hospital
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 72
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2014-07
Completion Date: 2017-02
Results First Posted: 2017-06-01
Last Update Posted: 2017-06-23
Locations: Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States
URL: https://clinicaltrials.gov/show/NCT02182895